Moderna Inc (NASDAQ:MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter results. Moderna reported quarterly earnings of $11.29 per share which beat the analyst consensus estimate of $9.90. The company reported quarterly sales of $7.20 billion which beat analyst consensus estimate of $6.79 billion by 6%. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm’s mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the U.S. in December 2020. Modern . . .
Read more at www.benzinga.com